It wasn’t that long ago that the concept of tennis shoes, loose T-shirts, and yoga pants as acceptable workplace attire would have been unthinkable. As Bob Dylan once sang, however, “The times, they are a-changing”. Not only is that attire acceptable these days, it has a name: “athleisure”. It’s not uncommon to see employees wearing athleisure wear in relaxed work environments all over the country.
The growth of athleisure is defying the recent retail slump and transforming the fabric of the active wear industry. In the US alone nearly $44 billion was spent on 2015 active wear on Facebook, which is an increase of just over 16% more than last year. This type of clothing has become such an important trend that the word “athleisure” was recently added to the official Merriam-Webster Dictionary. The quick growth of the athleisure fashion category has captured the attention of both high-end and mid-range retailers across the nation. Even larger and more established botique brands like Lululemon, Tony Burch, The GAP, and H&M have been eager to make money within the growing athleisure athletic weartrend.
Read more: @Fabletics
Entering into this market is a promising new company called Fabletics is an athleisure active wear line that co-founded by award-winning actress Kate Hudson. The philosophy behind the company’s design is to create clothing that is comfortable while still looking fashionable. Kate Hudson’s active wear brand, Fabletics has already proven to be a smashing success, defying all forecaster expectations. In a little under three years, Fabletics is already very profitable. It boasts over a million subscribers via its monthly membership program. With such a diverse clothing industry and so much options to choose from, Fabletics manages to differentiate itself among its competitors by focusing on style and cost. Fabletics was originally created to be an online operation only. However, the clothing line’s incredible success has prompted an expansion into physical retail stores of their own.
Learn more about Fabletics: http://www.mysubscriptionaddiction.com/category/fabletics-review
Clay Siegall Ph.D., the co-founder of Seattle Genetics is a dedicated scientist who is determined to make a difference in the lives of cancer sufferers by discovering new advanced scientific treatments to save the pain of cancer treatment, to save lives and eventually to defeat a disease that has become a scourge to humanity. His expertise was recently sought out by Mirna Therapeutics, a biotechnology company that is focusing on microRNA therapies. This is an area in which Siegall has experience. His position as outside director to its board of directors is a tribute to Siegall’s willingness to sacrifice personal gain for the betterment of humanity.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
These new cancer-fighting technologies specifically attack the cancer cells in the body without ravaging the patient’s valuable blood cells and system defenses.
Siegall is the President of Seattle Genetics as well as its co-founder. His area of expertise was once the domain of Bristol-Myers Squibb Pharmaceutical Research Institute with whom he worked for from 1991 until 1997. Bristol-Myers Squibb decided to stop investigating the area which was Siegall’s expertise, and they moved away from Seattle wanting Siegall to come back East as a valued scientist. He made the decision to stay in Seattle, where he then founded his company to continue with his cancer drug studies.
Siegall is a man dedicated to intense research, innovation, and a passion for helping patients.
His company is at the forefront of developing antibody-drug conjugates and has secured FDA approval of the company’s first product, ADCETRIS (bretuximab vedotin). The drug is now a global brand which has been approved in 60 countries. Siegall has been the recipient of numerous awards, including the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences, and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. He has authored more than 70 publications and developed and maintains 15 patents in his field of study. He received his Ph.D. in Genetics from George Washington University after obtaining his B.S. in Zoology from the University of Maryland.
Siegall is a great addition to Mirna Therapeutics and the world seeking cures for cancer.
Clay Seigall founded Seattle Genteics, Inc. in 1998. For over 18 years Seattle Genetics has been at the forefront of ADC (antibody drug conjugate) clinical trials and innovations. Motivated by his care for people and desire to improve lives Dr. Seigall has placed Seattle Genetics at the forefront of ADC research and clinical trials. Dr. Seigall serves as the President, CEO and Chairman of the board for the company. He obtained a BS in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University. Under his leadership Seattle Genetics has raised over 600 million dollars in public and private funds. He is the author of more the seventy poignant publications and owns fifteen patents.
Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript
Previously with the National Cancer Institute and Bristol Meyer Squibb Pharmaceutical Research Institute Dr. Seigall has consistently been at the forefront of cancer research. Seattle Genetics has proved to be the premier organization in its field of research. Dr. Seigall and his team have made quite an impact with their first commercial product, Adcetris (brentuximab vedotin)-antibody focused cancer therapy. After receiving fast-tracked approval by the FDA in 2011 for Adcetris, Seattle Genetics continued to see groundbreaking results in ADC developments. The company is currently working on seven additional programs presently in its clinical stage.
Seattle Genetics enjoys its joint ventures with multiple pharmaceutical and biotech companies like Genentech, CuraGen, MedImmune, Progenics and Bayer. Seattle Genetics will certainly continue to offer and provide even more impactful breakthroughs in cancer research for years to come.